Neumora Therapeutics Future Growth
Future criteria checks 0/6
Neumora Therapeutics is forecast to grow earnings and revenue by 15.2% and 74.8% per annum respectively. EPS is expected to grow by 23.8% per annum. Return on equity is forecast to be -65% in 3 years.
Key information
15.2%
Earnings growth rate
23.8%
EPS growth rate
| Pharmaceuticals earnings growth | 23.7% |
| Revenue growth rate | 74.8% |
| Future return on equity | -65.0% |
| Analyst coverage | Good |
| Last updated | 23 Sep 2024 |
Recent future growth updates
No updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 38 | -301 | -271 | -289 | 6 |
| 12/31/2025 | N/A | -276 | -246 | -250 | 7 |
| 12/31/2024 | N/A | -240 | -217 | -202 | 7 |
| 6/30/2024 | N/A | -274 | -204 | -198 | N/A |
| 3/31/2024 | N/A | -254 | -179 | -173 | N/A |
| 12/31/2023 | N/A | -236 | -168 | -163 | N/A |
| 9/30/2023 | N/A | -155 | -142 | -142 | N/A |
| 6/30/2023 | N/A | -132 | -120 | -120 | N/A |
| 3/31/2023 | N/A | -123 | -116 | -116 | N/A |
| 12/31/2022 | N/A | -131 | -128 | -115 | N/A |
| 9/30/2022 | N/A | -130 | -128 | -114 | N/A |
| 6/30/2022 | N/A | -278 | -119 | -105 | N/A |
| 3/31/2022 | N/A | -265 | -106 | -92 | N/A |
| 12/31/2021 | N/A | -237 | -76 | -75 | N/A |
| 9/30/2021 | N/A | -230 | -65 | -63 | N/A |
| 12/31/2020 | N/A | -99 | -28 | -27 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NMRA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: NMRA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: NMRA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: NMRA is forecast to have no revenue next year.
High Growth Revenue: NMRA is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: NMRA is forecast to be unprofitable in 3 years.